Showing 20 of 46 recruiting trials for “splenic-marginal-zone-lymphoma”
Rituximab Plus Venetoclax in Front Line Marginal Zone Lymphoma
👨⚕️ Gottfried von Keudell, MD, PhD, Beth Israel Deaconess Medical Center📍 1 site📅 Started Feb 2026View details ↗
A Study of Rocbrutinib Versus Investigator's Choice of BTK Inhibitors in Patients With Relapsed or Refractory Mantle Cell Lymphoma
Exploratory Study of Orelabrutinib in the Treatment of Early-stage Untreated MZL
👨⚕️ Shuhua yi, Hematology Hospital, Chinese Academy of Medical Sciences📍 14 sites📅 Started Jan 2026View details ↗
Orelabrutinib as Consolidation and Maintenance Therapy in Treatment-Naïve MZL.
Epcoritamab in Patients With Newly Diagnosed Marginal Zone Lymphoma (MZL)
RecruitingNCT06712459 ↗
Integrated Molecular and Clinical Profiling of Transformed Splenic Marginal Zone Lymphoma
👨⚕️ Luca Arcaini, MD, Fondazione IRCCS Policlinico San Matteo📍 7 sites📅 Started Oct 2025View details ↗
Orelabrutinib Plus Lisaftoclax and Rituximab in Untreated Mantle Cell Lymphoma With High-Risk Disease
A Study to Evaluate Acalabrutinib, in Combination With the R-CHOP Standard of Care, for Previously Untreated Mantle Cell Lymphoma in Spain
Orelabrutinib Combined With Zebetuzumab and Lenalidomide for the Treatment of Newly Diagnosed MZL
🏥 The First Affiliated Hospital with Nanjing Medical University📍 1 site📅 Started Aug 2025View details ↗
HM2023-43:Ph 2 Trial of Tafasitamab With Lenalidomide+Rituximab in Treatment-naive FL and MZL
Pomalidomide Plus Orelabrutinib and Zuberitamab in Untreated Mantle Cell Lymphoma
Acalabrutinib Plus Rituximab for the Treatment of Elderly or Low- to Intermediate-Risk Younger Untreated Mantle Cell Lymphoma
Orelabrutinib Combined With Rituximab ± Lenalidomide in Response-Adapted Stratified Therapy for Untreated MZL
🏥 The First Affiliated Hospital with Nanjing Medical University📍 1 site📅 Started Apr 2025View details ↗
A Study to Investigate the Efficacy and Safety of Sonrotoclax Plus Zanubrutinib Compared With Placebo Plus Zanubrutinib in Adults With Relapsed/Refractory Mantle Cell Lymphoma (CELESTIAL-RRMCL)
Pirtobrutinib in Combination With Rituximab in Adults With Untreated Marginal Zone Lymphoma (PIONEER-MZL)
RecruitingNCT06788652 ↗
A Study of Patients With Relapsed/Refractory Mantle Cell Lymphoma Treated With Lisocabtagene Maraleucel in the Post-Marketing Setting
GATE1: A Multicenter Phase II Study of Pirtobrutinib, Rituximab and Venetoclax Combination Therapy for Patients With Previously Untreated Mantle Cell Lymphoma
A Phase 2 Trial of Mosunetuzumab and Zanubrutinib for Patients With Relapsed/Refractory Marginal Zone Lymphoma
Orelabrutinib Combined With Rituximab Versus R-CVP in the Untreated MZL： A Randomized, Open Phase II Trial
👨⚕️ Fei Li, professor, The First Affiliated Hospital of Nanchang University📍 1 site📅 Started Dec 2024View details ↗
Mosunetuzumab in Patients With Newly Diagnosed Extranodal Marginal Zone Lymphoma
Page 1 of 3Next →
Get alerts when new trials open
Create a free account to follow conditions and receive trial notifications.
Create free account →